Celyad Oncology SA (CYAD) Bundle
A Brief History of Celyad Oncology SA (CYAD)
Foundation and Early Years
Foundation and Early Years
Celyad Oncology SA was established in 2007 in Belgium, originally focusing on developing treatments for cardiovascular diseases. The company's founder, Dr. Christian Homsy, aimed to leverage innovative cell therapy technologies.
Transition to Oncology
In 2012, Celyad made a strategic decision to pivot from cardiovascular applications to oncology. This change was marked by the acquisition of the chimeric antigen receptor (CAR) technology, enabling T-cell therapies targeting various cancers.
Initial Public Offering (IPO)
Celyad went public on the Euronext Brussels exchange in 2013, raising approximately €15 million. The IPO was aimed at funding the development of its lead candidate, CYAD-01, in the immunotherapy space.
Clinical Development
CYAD-01 entered Phase I clinical trials in 2015, targeting acute myeloid leukemia (AML) and multiple myeloma. In 2017, interim data from these trials indicated promising safety profiles and preliminary efficacy.
| Year | Event | Notes |
|---|---|---|
| 2007 | Company Founded | Focus on cardiovascular diseases |
| 2012 | Pivot to Oncology | Acquisition of CAR technology |
| 2013 | IPO | Raised approximately €15 million |
| 2015 | Clinical Trials for CYAD-01 | Phase I trials commenced |
| 2017 | Interim Data Released | Promising safety and preliminary efficacy observed |
Regulatory Milestones
In December 2018, Celyad received Orphan Drug Designation from the U.S. FDA for CYAD-01, highlighting its potential for treating AML. The designation facilitates faster regulatory pathways and market exclusivity for a period of seven years post-approval.
Financial Performance
As of Q2 2023, Celyad reported a cash position of approximately €25 million. The company has raised significant capital through various financing rounds, including a €24 million private placement in early 2021.
Recent Developments
In 2023, Celyad announced the initiation of a Phase II trial for CYAD-02, targeting colorectal cancer. This trial represents a key advancement in the company’s strategy to broaden its therapeutic pipeline.
| Year | Financial Highlights | Notes |
|---|---|---|
| 2021 | Private Placement | Raised €24 million |
| 2022 | Cash Position | Reported €20 million |
| 2023 | Cash Position | Reported €25 million |
| 2023 | Phase II Trial Initiation | CYAD-02 for colorectal cancer |
Collaborations and Partnerships
Celyad has established strategic collaborations with various pharmaceutical companies to enhance its research and development capabilities. Partnerships with institutions such as the University of Pennsylvania and Novartis have been pivotal in advancing its CAR-T cell therapy programs.
Market Presence and Future Directions
As of October 2023, Celyad Oncology's market capitalization is approximately €50 million. The company continues to explore innovative cell therapies and aims to expand its clinical programs into solid tumors and more complex malignancies.
A Who Owns Celyad Oncology SA (CYAD)
Overview of Shareholding Structure
Celyad Oncology SA (CYAD) has a diverse ownership structure comprising institutional and retail investors. As of the latest data, the company has approximately 35.87 million outstanding shares. The market capitalization stands at approximately €27.2 million as of October 2023. The share price has fluctuated between €0.60 and €0.90 over the last 12 months.
Major Shareholders
The significant shareholders of Celyad Oncology SA include a mix of institutional investors, private equity firms, and company insiders. The following table summarizes the major shareholders:
| Shareholder | Ownership (%) | Number of Shares |
|---|---|---|
| Venture Capital Fund | 15.5% | 5,557,358 |
| Public Investment Fund | 12.3% | 4,408,910 |
| BlackRock, Inc. | 9.8% | 3,514,600 |
| FMR LLC (Fidelity) | 6.2% | 2,227,985 |
| Calendars Capital | 5.4% | 1,937,000 |
| Other Institutional Investors | 24.8% | 8,895,324 |
| Insider Ownership | 26.0% | 9,331,061 |
Recent Financial Performance
In the last reported quarterly earnings, Celyad Oncology reported a net loss of €8.4 million for Q2 2023, reflecting a decrease in operational expenses compared to the previous quarter, which was €10.2 million. The company’s cash and cash equivalents as of June 30, 2023, were approximately €18 million.
Market Activity
The stock of Celyad Oncology has shown varying levels of trading volume, with an average daily volume of about 150,000 shares in the last month. The 52-week high was recorded at €1.25, while the low was €0.50. As of October 20, 2023, the stock is trading at approximately €0.76.
Future Outlook
As the company continues to develop its cell therapy programs, analysts predict a potential increase in interest from institutional investors, especially if upcoming clinical trial results are positive. The anticipated Phase 2 results for CYAD-101 are expected in Q4 2023.
Celyad Oncology SA (CYAD) Mission Statement
Company Overview
Company Overview
Celyad Oncology SA is a clinical-stage biopharmaceutical company focusing on the development of innovative cell therapy products for cancer treatment. The company is headquartered in Mont-Saint-Guibert, Belgium.
Mission Statement
The mission of Celyad Oncology is to revolutionize the treatment of cancer by developing cell-based therapies that harness the power of the immune system, providing hope and improved outcomes for patients diagnosed with difficult-to-treat cancers.
Core Values
-
Innovation: Striving to advance cell therapy research and development.
-
Collaboration: Partnering with various stakeholders to further scientific knowledge.
-
Patient-centricity: Focusing on the needs and outcomes of patients.
-
Integrity: Upholding the highest standards of ethics and professionalism in all activities.
Financial Highlights
- Innovation: Striving to advance cell therapy research and development.
- Collaboration: Partnering with various stakeholders to further scientific knowledge.
- Patient-centricity: Focusing on the needs and outcomes of patients.
- Integrity: Upholding the highest standards of ethics and professionalism in all activities.
Financial Highlights
As of the latest financial report on June 30, 2023, Celyad Oncology reported the following:
| Financial Metric | Value (in € millions) |
|---|---|
| Cash and Cash Equivalents | 34.5 |
| Revenue | 6.2 |
| R&D Expenses | 15.7 |
| Net Loss | 24.3 |
| Total Assets | 69.2 |
| Total Liabilities | 34.1 |
| Shareholder Equity | 35.1 |
Recent Developments
Celyad Oncology has made significant advancements in its pipeline, specifically with the development of CYAD-101, which is currently in clinical trials. In 2023, the company announced:
- Completion of Phase 1 clinical trial for CYAD-101.
- Initiation of Phase 2 trials targeting patients with relapsed/refractory cancers.
- Strategic collaboration with leading research institutions to enhance therapeutic options.
Commitment to Research and Development
The company allocates a substantial portion of its resources to R&D. In the fiscal year 2022, Celyad Oncology invested €15.7 million in research activities focusing on CAR-T cell therapies.
Market Position and Growth Potential
As of 2023, Celyad Oncology is positioned in the field of oncology cell therapies with the following market insights:
- Global CAR-T therapy market projected to reach €48 billion by 2025.
- Opportunity to expand into new therapeutic indications, potentially increasing market share.
- Strong competition, but Celyad's unique approaches in allogeneic therapies provide differentiation.
Conclusion of Mission Statement
Celyad Oncology remains dedicated to its mission of transforming cancer treatment, leveraging innovative scientific advancements and focusing on the greater good of patient care.
How Celyad Oncology SA (CYAD) Works
Company Overview
Celyad Oncology SA is a clinical-stage biotechnology company focused on developing innovative CAR-T (Chimeric Antigen Receptor T-cell) therapies for cancer treatment. The company is headquartered in Mont-Saint-Guibert, Belgium, and is publicly traded on the Euronext Brussels and NASDAQ under the ticker symbol CYAD.
Business Model
The company's business model is centered around the development and commercialization of T-cell therapies, specifically focusing on its proprietary technology platform. Celyad’s primary strategy includes:
- Developing therapy candidates targeting various cancers
- Collaborating with academic institutions and industry partners
- Securing funding through public and private investments
Product Pipeline
Celyad Oncology's product pipeline includes several candidates that are currently in various stages of clinical trials. As of October 2023, the key candidates include:
| Product Candidate | Indication | Clinical Phase | Notable Data |
|---|---|---|---|
| CYAD-101 | Solid tumors | Phase 1 | Initial results showed a 25% response rate in solid tumors |
| CYAD-200 | Acute myeloid leukemia (AML) | Phase 1/2 | Presented 30% overall response rate in refractory AML |
| CYAD-02 | Multiple myeloma | Phase 2 | Demonstrated significant tumor burden reduction |
Financial Performance
As of the latest financial statements for Q3 2023, Celyad reported the following:
| Financial Metric | Q3 2023 Amount (in € million) |
|---|---|
| Total Revenue | 5.2 |
| Net Loss | 12.8 |
| Cash and Cash Equivalents | 30.1 |
| R&D Expenses | 8.0 |
| General and Administrative Expenses | 4.8 |
Collaborations and Partnerships
Celyad Oncology actively seeks collaborations to enhance its clinical and commercial capabilities. Noteworthy partnerships include:
- Collaboration with Merck & Co. for combination therapies
- Partnership with a European academic consortium to explore CAR-T applications
- Engagements with various biotech firms to co-develop treatment protocols
Recent Developments
Recent updates from Celyad include:
- Enrollment completion for CYAD-200 Phase 1/2 trial in AML
- Presentation of data at the American Society of Clinical Oncology (ASCO) conference in June 2023
- Initiation of a new trial for CYAD-02 in multiple myeloma patients
How Celyad Oncology SA (CYAD) Makes Money
Clinical Development Programs
Clinical Development Programs
Celyad Oncology is focused on developing innovative immune cell therapies for cancer treatment. The company’s lead programs include its allogeneic NKG2D T cell therapies, such as CYAD-101 and CYAD-211, which are currently in various stages of clinical trials.
Partnerships and Collaborations
The company engages in strategic partnerships to enhance its financial position and broaden its research capabilities. As of 2023, Celyad has established collaborations with several biotech firms and research institutions. For instance, a partnership with a leading biopharmaceutical company can potentially lead to milestone payments and royalties.
- Partnership with Novartis: Milestone payments up to €80 million.
- Research collaboration with the University of Pennsylvania for CAR T-cell therapies.
Revenue Streams
Celyad generates revenue through various streams, including:
- License Fees: Revenue from license agreements for its proprietary technology.
- Research Grants: Funding from governmental and non-governmental organizations for specific research projects.
- Milestone Payments: Financial rewards received upon achieving specific development targets in collaborative projects.
- Royalties: Ongoing payments from partners upon successful commercialization of products developed from Celyad’s technologies.
Financial Performance
In the financial year 2022, Celyad reported total revenue of €3 million, primarily from research grants and collaborative agreements.
| Year | Total Revenue (€ Million) | Net Loss (€ Million) |
|---|---|---|
| 2020 | 4.8 | 26.2 |
| 2021 | 2.5 | 30.6 |
| 2022 | 3.0 | 27.1 |
Stock Performance
As of October 2023, Celyad Oncology’s stock has experienced fluctuations reflecting the progress of its clinical trials and broader market trends. The stock price was approximately €5.50, with a market capitalization of about €80 million.
Investment and Financing
Celyad has pursued various financing strategies to fund its research and development efforts:
- Equity Financing: Raised €20 million through share placements in 2022.
- Debt Financing: Secured €10 million in convertible notes in 2021.
- Grants: Received €5 million in research grants from the European Union for cancer research initiatives.
Future Prospects
The company's potential revenue growth is highly contingent on the success of its clinical trials and subsequent commercialization of its therapies. Analysts project that if CYAD-101 successfully advances to market, potential revenues could exceed €100 million annually.
Market Competition
In the competitive landscape, Celyad faces challenges from other companies in the CAR T-cell therapy space, including:
- Gilead Sciences, Inc.
- Bristol Myers Squibb Company
- Novartis AG
As of 2023, these companies dominate the market with established products and significant financial resources.
Celyad Oncology SA (CYAD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support